Drug Profile
Research programme: metabolic disorder therapeutics - Versantis
Alternative Names: VS-03Latest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator Genfit; Versantis
- Class Drug withdrawal therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acidaemia
- No development reported Substance-related disorders